GTF3C3 Antibody

What is GTF3C3 and what are its primary cellular functions?

GTF3C3 (General Transcription Factor IIIC, Polypeptide 3, 102kDa) functions as an integral, tightly associated component of the DNA-binding TFIIIC2 subcomplex that directly binds tRNA and virus-associated RNA promoters . This protein plays a crucial role in RNA polymerase III-mediated transcription, which is responsible for synthesizing essential non-coding RNAs necessary for cellular function . GTF3C3 is localized primarily in the nuclear membrane, nucleolus, and nucleoplasm .

The protein is a critical factor in the initiation of transcription by RNA polymerase III. Dysregulation of RNA polymerase III activity has been linked to various diseases, including cancer and neurodevelopmental disorders . Recent research has demonstrated that biallelic variants in GTF3C3 are associated with a specific neurodevelopmental syndrome characterized by microcephaly, developmental delay, and intellectual disability .

Confirming antibody specificity is crucial for reliable experimental outcomes. For GTF3C3 antibodies, researchers should implement the following validation approaches:

• Positive control samples: Use cell lines known to express GTF3C3, such as HepG2, HeLa, 293T, RAW264.7, and NIH/3T3, which have been documented as positive samples for GTF3C3 detection .

• Molecular weight verification: Confirm that the observed molecular weight matches the expected 101kDa for GTF3C3 .

• Knockdown/knockout validation: Compare antibody signal between wild-type samples and those with reduced GTF3C3 expression through RNA interference or CRISPR-Cas9 approaches.

• Immunoprecipitation followed by mass spectrometry: This method can provide definitive confirmation of antibody specificity.

• Cross-reactivity assessment: When working with non-human samples, consider sequence homology. For example, GTF3C3 sequence identity varies across species: Horse (92-93%), Rabbit (85-86%), Rat (92%), Cow (79%), Dog (79%), Guinea Pig (77%), and Pig (79%) .

How should researchers optimize experimental protocols for detecting GTF3C3 in patient samples when investigating neurodevelopmental disorders?

Recent studies have identified biallelic variants in GTF3C3 as causative factors in a novel autosomal recessive form of syndromic intellectual disability . When investigating GTF3C3 in patient samples:

• Tissue selection: Brain tissue samples are ideal when available, but fibroblasts have been successfully used in recent studies examining GTF3C3 variants . Patient 5 from a recent study harboring compound heterozygous GTF3C3 missense variants (c.503C>T p.(Ala168Val) and c.2419C>T p.(Arg807Cys)) was successfully analyzed using cultured skin fibroblasts .

• Variant detection protocol:

  • For mRNA splicing analysis, treat cells with cycloheximide (CHX) to inhibit nonsense-mediated mRNA decay

  • Perform RT-PCR with primers spanning relevant exons (e.g., exons 3 and 5 for the c.503C>T variant)

  • Confirm aberrant splicing through Sanger sequencing of PCR products

• Protein expression analysis:

  • Western blot analysis with normalization to housekeeping proteins (β-actin and GAPDH)

  • Include at least three experimental replicates with technical duplicates

  • Use statistical analysis (e.g., Dunnett's multiple comparison test) when comparing patient samples to controls

The most common GTF3C3 variants identified in neurodevelopmental disorders include:

• c.503C>T p.(Ala168Val) - affects a highly conserved alanine residue at position 20 in a TPR domain

• c.1268T>C p.(Leu423Pro) - located in a TPR domain

• c.1436A>G p.(Tyr479Cys) - results in a substitution at position 24 in TPR domain 8

• c.2419C>T p.(Arg807Cys) and c.2420G>A p.(Arg807His) - affect a conserved arginine residue

• c.1279G>T p.(Val427Phe) - identified in Family 1 in homozygous state

• c.514T>G p.(Cys172Gly) - identified in Family 2 in homozygous state

• c.1525G>A p.(Ala509Thr) - maternal inherited missense variant in Family 3

• c.2149C>T p.(Arg717Ter) - paternal inherited stop gain variant in Family 3

What are the most effective experimental designs for investigating GTF3C3's role in RNA polymerase III transcription mechanisms?

To investigate GTF3C3's role in RNA polymerase III transcription:

• RNA polymerase III reporter gene assays: These have been successfully used to demonstrate that missense variants in GTF3C3 result in loss of function . Design experiments to measure transcription of RNA polymerase III targets with and without functional GTF3C3.

• Chromatin immunoprecipitation (ChIP): Use GTF3C3 antibodies to identify genomic binding sites and correlate them with RNA polymerase III transcription units. Recommended protocol steps:

  • Crosslink protein-DNA complexes with formaldehyde

  • Sonicate chromatin to 200-500bp fragments

  • Immunoprecipitate with GTF3C3 antibody (3 μg per reaction recommended)

  • Analyze by qPCR or sequencing

• Protein-protein interaction studies:

  • Immunoprecipitation with GTF3C3 antibodies followed by mass spectrometry

  • Proximity ligation assays to identify interactions with other TFIIIC subunits

  • Yeast two-hybrid screening

• Animal models: Zebrafish and Drosophila models have successfully recapitulated key phenotypes of GTF3C3 deficiency :

  • Zebrafish knockout models showed microcephaly, brain anomalies, and seizure susceptibility

  • Reduced RNA polymerase III target gene expression was observed in zebrafish knockouts

  • Neuronal loss of Gtf3c3 in Drosophila induced seizure-like behavior, motor impairment, and learning deficits

How do post-translational modifications affect GTF3C3 function and antibody recognition?

While the search results don't specifically address post-translational modifications (PTMs) of GTF3C3, researchers should consider the following methodological approaches:

• Antibody selection based on epitope location: Choose antibodies targeting different regions of GTF3C3 to ensure detection regardless of PTM status. Available antibodies target various regions:

  • N-terminal region (amino acids 36-85)

  • N-terminal region (amino acids 47-76)

  • Middle region (amino acids 112-214)

  • Complete protein (amino acids 1-886)

• Phosphorylation analysis: Given GTF3C3's role in transcriptional regulation, phosphorylation likely affects its function. Researchers can:

  • Use phospho-specific antibodies if available

  • Perform phosphatase treatment prior to immunoblotting

  • Use Phos-tag gels to separate phosphorylated forms

• Other potential PTMs: Consider ubiquitination, SUMOylation, or acetylation, which commonly regulate nuclear proteins.

What approaches are recommended for investigating structural and functional relationships in GTF3C3?

GTF3C3 contains multiple tetratricopeptide repeat (TPR) domains that are critical for its function . To investigate structure-function relationships:

• Structural modeling: Use AlphaFold or similar tools as demonstrated in recent research on GTF3C3 variants. PremPS was used to predict significant changes in the 3D structure of the protein due to missense substitutions .

• Mutagenesis studies: Target:

  • Conserved TPR domains (particularly positions 8, 20, and 27 which are highly conserved)

  • Known disease-associated variants (e.g., p.Ala168Val, p.Leu423Pro, p.Tyr479Cys)

  • RNA-binding interfaces

• Minigene analysis: Particularly useful for investigating variants that might affect splicing. This approach confirmed that the recurrent c.503C>T p.(Ala168Val) variant introduces a cryptic donor site into exon 4, resulting in mRNA missplicing .

What are common challenges when working with GTF3C3 antibodies and how can researchers overcome them?

Several technical challenges may arise when working with GTF3C3 antibodies:

• Background signal in Western blots:

  • Optimize blocking conditions (5% skim milk in PBS buffer is recommended)

  • Titrate antibody concentration (try 0.2-1 μg/mL range)

  • Use highly specific secondary antibodies (HRP-conjugated anti-Rabbit IgG at 1:50,000-1:100,000)

• Weak signal detection:

  • Increase protein amount loaded (start with 20% of immunoprecipitated material from 1mg whole cell lysate)

  • Use enhanced chemiluminescence with extended exposure (3 minutes has been successful)

  • Consider using signal amplification systems

• Sample preparation for optimal GTF3C3 detection:

  • Nuclear extraction protocols are recommended as GTF3C3 is primarily nuclear

  • Avoid repeated freeze-thaw cycles of antibody preparations

  • For long-term storage, use 50% glycerol at -20°C (up to 1 year stability)

How can researchers interpret contradictory results when studying GTF3C3 expression patterns?

When faced with contradictory results:

• Antibody validation: Confirm specificity through multiple methods as outlined in question 1.3.

• Consider isoform-specific expression: GTF3C3 may exhibit tissue-specific isoforms or splice variants.

• Experimental conditions that can affect results:

  • Cell cycle stage (transcription factors often show cell cycle-dependent expression)

  • Confluence levels in cell culture (density can affect nuclear transcription factor expression)

  • Fixation methods (can affect epitope accessibility, particularly for nuclear antigens)

• Cross-validation approaches:

  • Use multiple antibodies targeting different epitopes

  • Compare protein detection with mRNA expression data

  • Implement orthogonal detection methods (mass spectrometry, CRISPR tagging)

How can GTF3C3 antibodies contribute to understanding the molecular basis of neurodevelopmental disorders?

Recent studies have established a clear link between GTF3C3 variants and neurodevelopmental disorders . GTF3C3 antibodies can facilitate research through:

• Developmental expression profiling: Map GTF3C3 expression during brain development using immunohistochemistry to identify critical developmental windows.

• Patient-derived models: Use GTF3C3 antibodies to assess protein expression and localization in:

  • Induced pluripotent stem cells (iPSCs) from patients

  • Brain organoids derived from patient iPSCs

  • Patient-derived fibroblasts (as demonstrated in recent research)

• Mechanistic investigations:

  • Assess RNA polymerase III target gene expression in patient cells using GTF3C3 ChIP-seq

  • Investigate protein interaction networks affected by pathogenic variants

  • Study potential therapy approaches restoring GTF3C3 function

The clinical features associated with GTF3C3 variants, which could be investigated using appropriate antibodies, include:

• Microcephaly

• Developmental delay/intellectual disability

• Distinctive dysmorphic facies

• Brain atrophy with predominant cerebellar involvement

• Hypoplasia of the frontal lobes

• Simplified gyral pattern

• Seizures (observed in approximately half of patients)

What are the latest methodological advances for studying GTF3C3's role in transcriptional regulation?

Recent methodological advances applicable to GTF3C3 research include:

• CUT&RUN and CUT&Tag: These techniques provide higher resolution mapping of transcription factor binding sites compared to traditional ChIP-seq, with lower background and input material requirements.

• Proximity labeling techniques:

  • BioID or TurboID fused to GTF3C3 to identify proximal interacting proteins

  • APEX2-based approaches for temporal resolution of interactions

• Cryo-EM structural studies: Recent advances have enabled structural determination of large transcription factor complexes, which could be applied to study GTF3C3 in the context of the TFIIIC2 complex.

• Single-cell approaches:

  • scRNA-seq to identify cell types most affected by GTF3C3 dysfunction

  • scATAC-seq to investigate chromatin accessibility changes

• Animal models: Established zebrafish and Drosophila models provide powerful systems for:

  • In vivo imaging of brain development

  • Behavioral assays correlating with human clinical features

  • Drug screening for compounds that rescue GTF3C3-deficient phenotypes

What are promising research areas for GTF3C3 investigation beyond neurodevelopmental disorders?

Beyond neurodevelopmental disorders, researchers should consider investigating:

• Cancer biology: Dysregulation of RNA polymerase III activity has been linked to cancer . Study areas include:

  • GTF3C3 expression patterns across cancer types

  • Correlation between GTF3C3 levels and cancer progression

  • Potential use as a biomarker or therapeutic target

• Aging and neurodegeneration: RNA metabolism dysfunction is implicated in neurodegeneration. Research could explore:

  • Age-related changes in GTF3C3 expression

  • Role in maintaining proteostasis through tRNA regulation

  • Potential links to neurodegenerative diseases

• Cellular stress responses: As a transcription factor involved in non-coding RNA synthesis, GTF3C3 may play roles in:

  • Adaptation to metabolic stress

  • Cellular responses to DNA damage

  • Regulation of protein synthesis under stress conditions

How might collaborative research approaches advance understanding of GTF3C3 function?

Advancing GTF3C3 research will benefit from multidisciplinary collaborations:

• Clinical-basic science partnerships: The discovery of GTF3C3-related neurodevelopmental disorders was facilitated by GeneMatcher, connecting researchers studying similar patients . Future work should continue:

  • Expanding patient cohorts through international registries

  • Detailed phenotyping correlated with specific variants

  • Natural history studies of GTF3C3-related disorders

• Cross-species comparisons: Combining data from:

  • Human patient samples

  • Zebrafish models (which have shown microcephaly and seizures)

  • Drosophila models (which demonstrated motor and learning deficits)

  • Mammalian models

• Therapeutic development pipeline:

  • High-throughput screening platforms for drug discovery

  • Gene therapy approaches for loss-of-function variants

  • Antisense oligonucleotide strategies for splicing correction